Core Viewpoint - The company announced the repurchase and cancellation of a total of 1,798,500 restricted stocks due to the departure of four incentive recipients and unmet performance targets for the year 2024 [1][2][4]. Summary by Sections Repurchase and Cancellation Reasons - The repurchase and cancellation of restricted stocks were approved during the sixth board meeting on April 28, 2025, due to four incentive recipients leaving the company and not meeting the performance criteria for the second release period of the incentive plan [1][2][3]. Details of the Repurchase - The company will repurchase 186,000 shares from the four departing employees and an additional 1,612,500 shares due to unmet performance targets, totaling 1,798,500 shares [1][2][4]. - The repurchase price is set at 4.18 yuan per share, which may include interest from bank deposits [4]. Impact on Share Structure - Following the repurchase, the total number of shares will decrease from 375,925,005 to 374,126,505 [5]. Compliance and Legal Opinions - The board confirmed that the decision-making process and information disclosure comply with relevant laws and regulations, ensuring no harm to the rights of incentive recipients or creditors [6][8]. - Legal opinions affirm that the repurchase has obtained necessary approvals and adheres to the relevant regulations, indicating no significant impact on the company's financial performance [8].
浙江莎普爱思药业股份有限公司2023年股票期权与限制性股票激励计划部分限制性股票回购注销实施公告